Oligodeoxynucleotide CpG 7909 delivered as intravenous infusion demonstrates immunologic modulation in patients with previously treated non-Hodgkin lymphoma.
about
Early experience with novel immunomodulators for cancer treatmentTreatment of autoimmune cytopenia complicating progressive chronic lymphocytic leukemia/small lymphocytic lymphoma with rituximab, cyclophosphamide, vincristine, and prednisone.Treatment with LL-37 peptide enhances antitumor effects induced by CpG oligodeoxynucleotides against ovarian cancerToll-like receptor agonists in cancer therapy.Immunomodulatory Agents with Antivascular Activity in the Treatment of Non-Small Cell Lung Cancer: Focus on TLR9 Agonists, IMiDs and NGR-TNF.FimH can directly activate human and murine natural killer cells via TLR4In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II studyMantle cell lymphoma activation enhances bortezomib sensitivity.Blood dendritic cells suppress NK cell function and increase the risk of leukemia relapse after hematopoietic cell transplantationEarly development of the Toll-like receptor 9 agonist, PF-3512676, for the treatment of patients with advanced cancers.Cancer immunotherapy employing an innovative strategy to enhance CD4+ T cell help in the tumor microenvironmentThe pharmacokinetics of Toll-like receptor agonists and the impact on the immune system.The emergence of immunomodulation: combinatorial immunochemotherapy opportunities for the next decade.CpG and non-CpG oligodeoxynucleotides directly costimulate mouse and human CD4+ T cells through a TLR9- and MyD88-independent mechanismImmunotherapy with CpG-ODN in neoplastic meningitis: A phase I trial.Poly(I:C) and CpG-ODN combined aerosolization to treat lung metastases and counter the immunosuppressive microenvironment.Trial Watch: Experimental Toll-like receptor agonists for cancer therapyPhase I clinical trial of CpG oligonucleotide 7909 (PF-03512676) in patients with previously treated chronic lymphocytic leukemiaAdoptive immunotherapy combined with intratumoral TLR agonist delivery eradicates established melanoma in miceHigh efficacy of CpG-ODN, cetuximab and cisplatin combination for very advanced ovarian xenograft tumors.Development of TLR9 agonists for cancer therapyHuman papillomavirus therapeutic vaccines in head and neck tumors.Systemic delivery of chTNT-3/CpG immunoconjugates for immunotherapy in murine solid tumor modelsCPG-7909 (PF-3512676, ProMune): toll-like receptor-9 agonist in cancer therapy.New adjuvants: EU regulatory developments.Toll-like receptor 9 (TLR9) agonists in the treatment of cancer.Obstacles to effective Toll-like receptor agonist therapy for hematologic malignancies.Twelve immunotherapy drugs that could cure cancers.In vitro synthesis of primary specific anti-breast cancer antibodies by normal human peripheral blood mononuclear cells.Intratumoral delivery of CpG-conjugated anti-MUC1 antibody enhances NK cell anti-tumor activity.Phase II study of a TLR-9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma.The Roles of Radiotherapy and Immunotherapy for the Treatment of LymphomaHeterogeneity of Toll-like receptor 9 signaling in B cell malignancies and its potential therapeutic application.Optimized systemic dosing with CpG DNA enhances dendritic cell-mediated rejection of a poorly immunogenic mammary tumor in BALB/c mice.DNA vaccines for the treatment of prostate cancer.Cancer immunotherapy and nanomedicine.Toll-like receptor signaling pathways--therapeutic opportunities.Immunomodulating antibodies and drugs for the treatment of hematological malignancies.Manipulation of cellular redox parameters for improving therapeutic responses in B-cell lymphoma and multiple myeloma.Immunotherapeutic potential of CpG oligodeoxynucleotides in veterinary species.
P2860
Q28241744-D92E4770-3B1C-45A5-8E35-2E205ED123D7Q33388795-C44C43F3-83D1-4CE3-B967-B9EA67239B96Q33792003-7676E510-18EA-43EE-90D4-1FC9845A99B8Q33918509-485A79D8-1FC9-43DE-855A-0E3E6A21383EQ33960866-038615AC-5E73-4FCE-A7CC-4EA8EA2A9FD2Q34025104-00845520-0980-4D35-8C1E-DD86A0273197Q34194680-E08B6C09-AF2C-4665-8AC1-09FB42231A0AQ34360347-D1F2FF52-C196-4010-90E7-F5F732A6096BQ34618829-00543B57-70D2-4362-8114-DA9402FA948EQ34619324-86871166-3131-4082-84DB-72812D080B41Q34757847-7BA525D9-0E3E-47C4-B130-07099EA161D5Q35018021-24E188C9-4082-4249-84CF-A384B2538C54Q35058213-E30EF20C-B8A4-4D01-B64A-9BAEEED64F7AQ35204579-1AA6A54B-52D1-4F84-AB60-57D816994B93Q36092885-939D46B1-022A-4800-955E-4878FE106CFAQ36107932-00666DC9-62A0-46B1-8FEE-8384C98CC554Q36194849-2E976EE7-E72D-49A1-9764-9444B6D74A55Q36222910-4ABB814A-156F-4397-9ED5-DBCA05EA9B11Q36403509-659D2BDF-4A37-4977-BE2B-C38230779818Q36608597-802193A7-2751-459B-BA9F-A41A535B0CF2Q36809776-CC64F9EA-9256-48C2-A7F1-D951F069AD7BQ36817148-74F302FD-732A-411D-B0AF-BAB52553858DQ36827406-5348CC54-BB88-4DEE-813A-E7EFEBEE04B8Q36909391-15690405-5338-4979-829C-C6F75448808AQ36968305-5BD36CD4-6F29-41C2-A50D-FB9D6D6D0C67Q37050998-90B77BF6-8C97-4685-BDAE-F66932C366E2Q37051022-A7AB115F-0CB0-4C34-83CF-F41FA84AFC7DQ37118201-86DB6715-12C7-4180-94E5-14CEC9742E80Q37220754-7154A70E-D9A2-4F04-93E5-2A73F394F081Q37322304-EFFCAEB5-3871-470F-BE1C-59C93524524DQ37354301-7C572AEE-25BE-4CAF-BF39-35E2C66CFC0BQ37640319-221DF1F3-6E90-44B7-8FB7-C5A3E02DB73CQ37671216-64DAF9E2-E956-41C9-8E07-95ABDFCD43C1Q37700490-D789A66F-5FF3-489B-8DA6-42A8DEC85A2FQ37771942-F4EEF16D-9D00-44BC-BB49-11756014ED94Q37785836-F28F50DA-A422-4EFC-B54D-96899979C0DFQ37803540-3D4DAF2E-AD78-4C07-A15B-32B1A42A6F55Q37832694-4EC7710A-F8A8-4AA7-B1B1-1FB41171E443Q37940343-AB636D74-DAA0-4CF1-963A-6D0521D3DAEFQ38131836-7545569A-1DB7-424D-A044-9F09EBEFE177
P2860
Oligodeoxynucleotide CpG 7909 delivered as intravenous infusion demonstrates immunologic modulation in patients with previously treated non-Hodgkin lymphoma.
description
2006 nî lūn-bûn
@nan
2006 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Oligodeoxynucleotide CpG 7909 ...... treated non-Hodgkin lymphoma.
@ast
Oligodeoxynucleotide CpG 7909 ...... treated non-Hodgkin lymphoma.
@en
type
label
Oligodeoxynucleotide CpG 7909 ...... treated non-Hodgkin lymphoma.
@ast
Oligodeoxynucleotide CpG 7909 ...... treated non-Hodgkin lymphoma.
@en
prefLabel
Oligodeoxynucleotide CpG 7909 ...... treated non-Hodgkin lymphoma.
@ast
Oligodeoxynucleotide CpG 7909 ...... treated non-Hodgkin lymphoma.
@en
P2093
P1476
Oligodeoxynucleotide CpG 7909 ...... treated non-Hodgkin lymphoma.
@en
P2093
Aaron D Bossler
Arthur M Krieg
Brian K Link
Daniel Weisdorf
George J Weiner
James E Wooldridge
Mary Shannon
Wendy L Rasmussen
P304
P356
10.1097/01.CJI.0000211304.60126.8F
P577
2006-09-01T00:00:00Z